Dr. Paul Turner -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Paul Turner, a Dermatology physician based in City, VA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Paul Turner has received $43,200.57 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Paul Turner has received a total of $43,200.57 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $43,200.57 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Paul Turner's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Speaking & Education$43,200.57Promotional speaking, CME events, and educational presentations

The largest payment category for Dr. Paul Turner is Speaking & Education, accounting for 100% ($43,200.57) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Paul Turner. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Novartis Pharmaceuticals$43,200.571

Dr. Paul Turner has a financial relationship with Novartis Pharmaceuticals, receiving $43,200.57 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

Drugs and Medical Devices Referenced in Payments

The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Paul Turner. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.

The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Paul Turner's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Paul Turner has received $43.2K across 1 pharmaceutical payments as a Dermatology physician in City, VA. Top paying companies include Novartis Pharmaceuticals ($43.2K). The doctor received a single, substantial payment of $43,201 in 2024. This payment represents 100% of the doctor's reported pharma payments, indicating a high concentration with one company. The payment was specifically for speaking engagement activities.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Paul Turner is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

Consider asking your doctor about any potential conflicts of interest or how industry payments might influence their treatment recommendations. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Paul Turner Compares to Other Dermatology Physicians

For dermatologists, payment profiles often show more diversified engagement across multiple companies and payment types.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Paul Turner in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Novartis Pharmaceuticals$43,200.57speakingXarelto2024-04-27Not Assessed

Frequently Asked Questions About Dr. Paul Turner's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Paul Turner received?

Paul Turner has received a total of $43.2K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Paul Turner taking too much pharma money?

Paul Turner has received $43.2K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Dermatology), the types of payments, and how they compare to peers. The largest payment category is speaking ($43.2K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Paul Turner?

The top pharmaceutical companies paying Paul Turner are: Novartis Pharmaceuticals ($43.2K). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Paul Turner receive?

Paul Turner's payments by type: speaking: $43.2K.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Paul Turner's payments compare to other Dermatology doctors?

To compare, look at the total amount ($43.2K), number of payments (1), and the types of payments received. Dermatology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Paul Turner's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1403671143). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Paul Turner's pharma payment profile?

The doctor's payment profile is dominated by a single transaction, making it difficult to assess broader engagement patterns. Paul Turner has received $43.2K in total pharma payments.

How does Paul Turner compare to peers in Dermatology?

For dermatologists, payment profiles often show more diversified engagement across multiple companies and payment types.

Are Paul Turner's pharma relationships typical for Dermatology?

The high concentration suggests a significant relationship with Novartis Pharmaceuticals.

What should patients of Paul Turner know about these payments?

Consider asking your doctor about any potential conflicts of interest or how industry payments might influence their treatment recommendations.

What patterns are visible in Paul Turner's payment history?

The payment is linked to a specific drug, Xarelto, which may indicate a focus on that therapeutic area.

Understanding This Doctor Payment Report

This transparency report for Dr. Paul Turner is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Paul Turner's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Paul Turner and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.